Literature DB >> 26451650

The role of visfatin (PBEF/Nampt) in pregnancy complications.

Tereza Pavlová1, Jan Novák2, Julie Bienertová-Vašků3.   

Abstract

Visfatin (PBEF/Nampt) is an adipocytokine that exerts pleiotropic effects within the human body, particularly affecting its metabolism and immunity. Visfatin was originally identified as being secreted by peripheral blood lymphocytes acting as a pre-B-cell colony-enhancing factor (PBEF). However, it was subsequently reported to be expressed in almost every tissue of the human body, with visceral fat deposits being the main source of visfatin. In addition to its secreted form, visfatin may also be found intracellularly where it functions as a nicotinamide phosphoribosyltransferase (Nampt). Visfatin maternal plasma concentrations increase during pregnancy, suggesting its important role in this complicated process. Alterations in visfatin level also take place in patients during pregnancy complications. This review focuses on the ones that most commonly occur in connection with visfatin: preterm labor, pre-eclampsia and gestational diabetes mellitus. The review aims to provide a better understanding of the role of visfatin during pregnancy and the causes of its alteration in maternal plasma, highlighting the potential use of visfatin as a diagnostic marker of pregnancy complications in the future.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Gestational diabetes mellitus; Maternal plasma; Pre-eclampsia; Preterm labor; Sirtuins; Visfatin

Mesh:

Substances:

Year:  2015        PMID: 26451650     DOI: 10.1016/j.jri.2015.09.004

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  7 in total

1.  Adipokine profiles in preeclampsia.

Authors:  Suchitra Chandrasekaran; Hayley Hunt; Susan Melhorn; Hilary S Gammill; Ellen A Schur
Journal:  J Matern Fetal Neonatal Med       Date:  2019-01-09

2.  Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.

Authors:  M R Luizon; A C T Palei; V A Belo; L M Amaral; R Lacchini; G Duarte; R C Cavalli; V C Sandrim; J E Tanus-Santos
Journal:  Pharmacogenomics J       Date:  2016-05-10       Impact factor: 3.550

3.  Evaluation of a Maternal Plasma RNA Panel Predicting Spontaneous Preterm Birth and Its Expansion to the Prediction of Preeclampsia.

Authors:  Carl Philip Weiner; Howard Cuckle; Mark Louis Weiss; Irina Alexandra Buhimschi; Yafeng Dong; Helen Zhou; Risa Ramsey; Robert Egerman; Catalin Sorin Buhimschi
Journal:  Diagnostics (Basel)       Date:  2022-05-27

4.  NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia.

Authors:  Daniela A Pereira; Valeria C Sandrim; Ana C Palei; Lorena M Amaral; Vanessa A Belo; Riccardo Lacchini; Ricardo C Cavalli; Jose E Tanus-Santos; Marcelo R Luizon
Journal:  Pharmacogenomics       Date:  2021-05-04       Impact factor: 2.638

5.  Adipokine Profile in Patients with Type 2 Diabetes Depends on Degree of Obesity.

Authors:  Joanna Kocot; Piotr Dziemidok; Małgorzata Kiełczykowska; Anna Hordyjewska; Grzegorz Szcześniak; Irena Musik
Journal:  Med Sci Monit       Date:  2017-10-19

6.  Plasma level and expression of visfatin in the porcine hypothalamus during the estrous cycle and early pregnancy.

Authors:  Tadeusz Kaminski; Marta Kiezun; Ewa Zaobidna; Kamil Dobrzyn; Barbara Wasilewska; Ewa Mlyczynska; Edyta Rytelewska; Katarzyna Kisielewska; Marlena Gudelska; Kinga Bors; Grzegorz Kopij; Karolina Szymanska; Barbara Kaminska; Agnieszka Rak; Nina Smolinska
Journal:  Sci Rep       Date:  2021-04-22       Impact factor: 4.379

Review 7.  From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases.

Authors:  Yumeng Zhu; Ping Xu; Xuan Huang; Wen Shuai; Li Liu; Shuai Zhang; Rui Zhao; Xiuying Hu; Guan Wang
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.